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Introduction: 
Aspirin, statins, angiotensin-converting enzyme inhibitors, and beta-blockers are cardiovascular 
medications that have been shown to reduce the risk of death, myocardial infarction and stroke in 
patients with cardiovascular disease (CVD)1-4. The Prospective Urban Rural Epidemiology 
(PURE) study demonstrated that the use of these medications for CVD secondary prevention is 
low worldwide, with rates of use of 40-66.5% in high-income countries, 11.8-30.0% in upper-
middle income countries, 4.3-21.9% in lower-middle income countries, and 3.3-9.7% in low-
income countries5.  
 
The reasons for the sub-optimal use of evidence-supported medications are likely to be 
multifactorial and context-specific. The patient-level factors shown to be associated with low 
adherence include pill load7, health literacy8, age9, ethnicity, education level, cognitive function, 
and employment status10-11. Additionally, the number of medications, side effects and the 
relationship with healthcare professionals (HCPs) are treatment-related and patient-provider 
related factors that may influence medication use11. Appropriate medication use is affected by all 
levels of the health system including the HCPs, the organization of hospitals, pharmacies and 
clinics, and the health policies and economic conditions under which the patients live and the 
HCPs work. A limited number of studies have examined health system barriers and facilitators 
associated with cardiovascular medication adherence, particularly in low and middle-income 
countries where rates of use are poorest12. Of the studies conducted, the use of combination 
pills13, subsidized medication costs through co-payments14,15, and physician, nurse or pharmacist 
counseling improved adherence in secondary prevention patients16-18. Given the absence of data 
in low-income countries, and the multifactorial causes of decreased adherence, additional 
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research is needed. Quantitative methodologies may be inadequate to capture the complexities 
and relationships among stakeholders of a healthcare system. Therefore, the objective of this 
paper is to explore the major obstacles and facilitators to the use of evidence-supported 
medications for secondary prevention of CVD using qualitative analysis in two diverse countries 
across multiple levels of their healthcare systems. These together may help strategize future 
major researches and policy.  
 
Methods: 
We conducted a qualitative descriptive study to explore the barriers and facilitators to CVD 
medication adherence in two settings, Hamilton, Canada and Delhi, India. We selected these two 
settings because they reflect a balance between contrasting economic status and health system 
structures and the feasibility of successfully carrying out the study. The units of analyses were 
the stakeholder groups involved in the study, which include: a) patients; b) physicians: family 
physicians, cardiologists, nurse practitioners, AYUSH (Ayurveda, Yoga and Naturopathy, 
Unani, Siddha, and Homoeopathy) physicians and c) non-physician healthcare workers 
(NPHWs): pharmacists, pharmaceutical companies, social workers, NGOs, nurses, hospital 
administrators, policy makers. In Canada, nurse practitioners complete additional educational 
training and have authority to prescribe medications. Given their advanced knowledge and 
responsibilities, we present the findings for physicians and nurse practitioners as one stakeholder 
group.  
 
The sampling methodologies used were specific to each context and stakeholder group (Table 1). 
In Canada, patients were sampled through purposeful sampling. The patients were identified 
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from the research investigators’ patient lists and patient referrals from other HCPs, and invited to 
participate in the study. Purposeful and snowball sampling were used to recruit physicians, 
pharmacists, social workers and policy makers. We identified these stakeholders through college 
referrals and invited potential respondents to participate by telephone and email. Additionally, 
we used the snowball sampling technique which involved asking the participants to refer other 
stakeholders with knowledge and experience that may be relevant to the study.  
 
In India, purposeful sampling was used to sample cardiologists, AYUSH physicians, and 
pharmacists. Hospitals in New Delhi and the National Capital Region with Cardiology and 
AYUSH departments were identified and contacted via email and telephone to recruit 
participants. Similarly, pharmacists within the region were contacted personally. Snowball 
sampling was used to recruit patients, nurses and hospital administrators. The participating 
cardiologists were asked to refer secondary prevention patients, administrators working within 
the hospital, and nurses on their service. Lastly, the policy makers working in the Department of 
Non-Communicable Disease within the Ministry of Health and Family Welfare, Government of 
India were contacted via email and telephone.  
 
In both contexts, in-depth, semi-structured interviews were conducted to explore the perceptions 
of cardiovascular medication use in secondary prevention, and the health system factors that 
influenced medication uptake. The interviews were undertaken by research assistants at a private 
location selected by the participants in New Delhi, and at the David Braley Research Institute, 
Hamilton General Hospital, Hamilton, ON, or by telephone. A total of 61 interviews were 
conducted in person and 8 were conducted via telephone. The interviews lasted between 30 and 
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60 minutes and consent was obtained for the interviews to be audio recorded. A final sample 
(n=69) of 23 patients, 10 physicians, 5 AYUSH physicians, 11 pharmacists, 2 nurse 
practitioners, 3 nurses, 4 hospital administrators, 1 social worker, 3 non-governmental 
organization (NGO) workers, 2 pharmaceutical company representatives and 5 policy makers 
participated in the study. Table 2-5 illustrates characteristics of the stakeholder groups. 
 
Data collection and analysis were completed concurrently from December 2014 to November 
2015. The interviews were transcribed verbatim with directed content analysis19 guiding initial 
coding and analysis to organize, summarize and categorize the data. Data analysis was 
completed by VM in Canada, and LN and MS in India by deriving codes, organizing the codes 
into broader categories, and collapsing the categories into themes and sub-themes. LN, MS and 
VM compared the emergent themes between the two countries to identify similarities and 
differences. Detailed theme summaries were written for each of the stakeholder groups in both 
countries.  
 
We used Guba and Lincoln’s (1994) criteria (credibility, transferability, confirmability, and 
dependability) to ensure trustworthiness in the qualitative findings20. Table 6 shows the strategies 
used. Research ethics approvals were obtained from the Hamilton Integrated Research Ethics 
Board and Institutional Ethics Committee, Public Health Foundation of India. Participants 






We present our findings under six main themes identified from analysis of the stakeholder 
groups’ responses. These themes encapsulate responses across the stakeholder groups and 
demonstrate the agreement or contrast among the groups. Additionally, the themes described 
within each stakeholder group are presented in the Appendix (Tables S1-12).  
 
Medication Counseling 
In Canada, physicians, nurses and pharmacists provided medication counseling to patients, while 
in India counseling was exclusively provided by physicians. The information provided during 
counseling included: the purpose of the medication, dosage, frequency, contraindications, side 
effects, adverse effects, instructions on how to take the medication and medication benefits. The 
physicians, nurse practitioners and pharmacists in Canada reported providing thorough 
medication counseling. In India, the physicians did not extensively discuss the purpose, benefits, 
or side effects of medications with patients due to time constraints. Additionally, they felt that 
notifying patients about potential side effect may decrease adherence. The primary mode used to 
communicate information about medications was exclusively verbal, except the Canadian 
pharmacist group who provided patients with written drug fact sheets for each prescription.  
 
The patients in India stated that they felt they lacked adequate information about medication side 
effects and they often attributed a multitude of physical discomforts to side effects of their 
medications.  
 
The physicians and nurse practitioners in Canada, and AYUSH practitioners in India included 
patients in the decision making when developing their treatment plan. Conversely, the physicians 
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in India indicated that joint-decision making does not regularly occur due to low patient 
education level and lack of desire to be included in treatment planning.  
 
“90% of [patients] are not involved and don’t want to get involved. They only want a remedy. They think doctor knows the best; 
that is the kind of wisdom they have which is not right but that is how they are brought up in their villages that if you have this 
problem go to the doctor he will give you the medicine and no questions. That is the kind of patients we deal with.” (Physician 4, 
female, 31 years of work experience, 730 patients /month, India) 
 
Monitoring Adherence 
In Canada and India, the physicians (allopathic and AYUSH) and nurses monitored patient 
medication adherence by asking the patient, checking biological markers (blood pressure, blood 
lipid levels), and examining the patient’s prescription history. The HCPs who reported discussing 
adherence with the patient included physicians, nurse practitioners, nurses and pharmacists. 
Additionally, the patients in Canada stated that their physicians regularly inquired about their 
medication adherence, whereas in India this was seldom reported.  
 
The physicians in Canada addressed poor adherence by providing the patient with additional 
information on the purpose and benefits of the medication, discussing the health implications of 
non-adherence, making recommendations to assist the patient with establishing a medication 
routine, involving family members to reinforce the importance of being adherent and trying to 
understand the factors affecting adherence.  
 
Medication availability  
In India, several patients stated that the nearest healthcare facility (public or private) and 
pharmacy were at considerable distance from their residence, particularly those residing in 
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rural areas. Many patients expressed distrust of private facilities and felt that better treatment 
was provided at government-funded hospitals, which required travelling further to receive 
treatment. The longer commute to access care and fill prescriptions resulted in considerable 
expenditure from lost wages, travel expenses, and older patients relied heavily on family 
members to procure their medications. The patients who were entitled to government 
subsidized medications indicated that they were required to commute to specific dispensaries 
and their medications were frequently unavailable.   
 
Medication affordability and drug coverage 
In Canada, physicians and pharmacists reported asking patients about medication affordability 
and coverage. Medication cost was the largest barrier to adherence reported by physicians, 
healthcare administrators and policy makers in India. However, the physicians in India stated 
that they did not overtly ask patients about medication affordability unless the patient explicitly 
stated that they were unable to afford their medications. Conversely, the physicians in Canada 
indicated that the minority of their patients experienced difficulties affording cardiovascular 
medications.  
 
Most patients in India stated that they received medication coverage through the central or state 
government scheme and they accessed the subsidized medications from government-funded 
hospitals monthly. Many patients chose to pay out of pocket to purchase medications from 
private sector pharmacies to ensure consistent access to medications.  
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“We are poor people. If we really were to buy medicines from outside, we would die. Thankfully we get free medicines from the 
government. We get free medicines from the hospital itself. We come here once in a month. Get all the medicines from the 
hospital itself.” (Patient 8, 62 years old, male, India).  
 
Within Canada, patients reported having medication coverage through employer health benefits 
programs, private insurance or government programs. The cost of medications was a barrier for 3 
of the 9 Canadian patients. These patients reported spending $40.00 to $300.00 per month on 
medications, including dispensing fees.  
 
“The biggest problem that I told [my cardiologist] is that I lost all my health coverage this February.  I told him that what I am 
going to do to, to save money is skip my pill one day and take them every other day.” (Patient 1, 59 years old, male, Canada). 
 
Within Canada, the physicians and pharmacists were aware and referred patients to several 
government programs to subsidize medication cost for patients with financial difficulties. The 
Canadian social worker reported regularly seeing patients with difficulties affording 
cardiovascular medications and recommended patients apply to the Ontario Trillium Benefit 
Plan, Ontario Works, and the Ontario Disability Support Program for assistance. She indicated 
that many patients are not aware of programs offered by the government to improve 
affordability, and approval for these programs could take several months.   
 
Additional strategies that were used by these stakeholder groups to improve medication 
affordability included: modifying the dose and frequency, and limiting the number of 
medications. Further, prescribing generic medications was a common practice used by the 
Canadian physicians. However, the physicians in India indicated that they based their prescribing 
practices on the information obtained from medical representatives which resulted in a greater 
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preference for prescribing branded medications. The use of poly-pills to reduce pill burden and 
improve medication affordability was not widely supported by the physicians in India because 
they felt that poly-pills could not be tailored to the specific patient.  
 
Within India, the pharmacists stated that many patients attempt to negotiate the cost of 
medications with the pharmacist, but high taxes, drug licenses, and permits prevented 
pharmacies from being able to offer medication discounts and rebates to patients. The 
pharmacists reported adhering to the prescriptions written by physicians even if generic 
medications were available as a more cost-effective option.  
 
Time Restrictions  
In both contexts, physicians (allopathic and AYUSH), nurses and healthcare administrators 
indicated that high patient workloads and time constraints affected the physician’s ability to 
spend an adequate amount of time counseling patients on their medication usage and adherence. 
The number of patients seen per day ranged from 75-185 for physicians in India and 7-55 for 
physicians in Canada. Further, the healthcare administrators in India stated that 160 to 1000 
patients were seen per day in the cardiology department.  
 
The Canadian patients were dissatisfied with the wait times to schedule appointments and short 
appointments durations. Many indicated that they were not able to spend an adequate amount of 






In Canada, the physicians discussed the importance of patients’ receiving follow-up by NPHWs 
as a means of reinforcing counseling on medication use. In addition to physicians and nurse 
practitioners, patients regularly interacted with residents/medical students, nurses, and 
hospital/community pharmacists.  
 
The physicians and pharmacists in Canada were also supportive of NPHWs taking on new roles 
and responsibilities in relation to renewing and modifying prescriptions, provided they 
completed training and certification. Further, the pharmacists felt comfortable prescribing 
medications for patients with stable cardiovascular conditions.  
 
“Many times a treatment is very algorithmic and a lot of cardiovascular medications do not have many risks so, I think someone 
can be easily trained in managing the first step such as blood pressure control or optimizing cardiovascular medication without 
too much risk; if they are presented with an algorithm or strategy to do so in a setting where a physician can be alerted. I think it 
has to be in a controlled environment then it’s a reasonable thing to do.”  (Physician 4, male, 5-10 patients per day, Canada).  
 
In contrast, in India, physicians were not supportive of NPHWs prescribing, modifying and 
renewing medications and they indicated a lack of clinical experience and expertise as the 
deterrent. However, the nurses indicated that short-term certification would be sufficient to 
provide them with the necessary knowledge to prescribe medications.  
 
Discussion: 
This qualitative study yielded several important findings. First, we found that the barriers to 
medication adherence did not differ substantially between the two contexts. The barriers that 
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were present in both Canada and India included: high patient loads, time constraints, medication 
affordability, and the absence of written counseling. Instead, limited medication counseling, 
adequate availability and accessibility to healthcare services and resistance to task shifting were 
barriers that were exclusive to India.  
 
Second, both contexts reported that monitoring adherence promoted better medication 
compliance. However, additional facilitators unique to Canada included adherence monitoring by 
NPHWs, inquiry and referral to programs to improve medication affordability, and task shifting 
medication renewal to NPHWs. Medication affordability was consistently recognized as a strong 
barrier to adherence across the stakeholder groups despite drug coverage availability in both 
countries. This finding is in line with previous research which has shown that lower out-of-
pocket medication expenses are associated with greater levels of adherence21-22 and adherence 
can be modestly improved when patients are provided with full medication coverage23. Within 
Canada, many adults do not have medication coverage and must pay out-of-pocket to cover some 
portion of their medication expenses24,25. Despite the availability of government drug programs, 
very few Canadian patients reported being familiar with these programs which suggests that 
public health agencies and HCPs should work to increase patient awareness and facilitate higher 
utilization rates. In India, the affordability of medications is heavily dependent on access to 
hospital formularies. Many patients chose to purchase medications out of pocket from private, 
community pharmacies to avoid long commutes, lost wages, and the unavailability of 
medications from hospitals formularies. Although the patients included in the study did not 
report medication unaffordability, this finding may be reflective of social stigma related to 
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disclosing financial information. Policies that extend the government-funded drug coverage to 
community-based pharmacies may address unaffordability and access to medications in India.  
 
We also demonstrated that the depth of counseling varied between Canada and India. In India, 
physicians regularly failed to discuss critical information with a patient when prescribing a 
medication. Medication indication9 and possible adverse effects26 may influence the patient’s 
adherence, both of which were not regularly discussed. A greater emphasis on counseling 
patients in India on the efficacy and effectiveness of generic medications may reduce self-
alteration of medication and improve the use of affordable generic drugs. In Canada and India, 
verbal information was the primary mode of counseling provided by HCPs and written materials 
were not routinely used. The duration of time spent counseling patients and a trusting physician-
patient relationship has been shown to be positively associated with adherence27-29. However, the 
HCPs in Canada and India indicated that time constraints inhibited their abilities to provide 
thorough medication counseling to patients.  
 
Third, in Canada, physicians were supportive of the redistribution of medication renewal and 
modification to NPHWs. Conversely, physicians in India stated that NPHWs lack the clinical 
expertise to manage cardiovascular medications. Several studies have demonstrated improved 
adherence30, health outcomes31, treatment concordance between physicians and NPHWs, and the 
cost-effectiveness of task shifting for chronic disease management32-33. Further, Adeyemo et al. 
showed that nurse-led follow up, counseling and medication prescription resulted in high rates of 
adherence in Nigerian hypertensive patients34, suggesting that it is a suitable intervention in 
middle and low-income countries.  
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Strength and Limitations: 
Our study has some limitations. First, the sample sizes for some of the stakeholder groups were 
small and may not reflect the perspectives of these groups, and the stakeholders included do not 
represent an exhaustive list of groups relevant to the health system. A limited number of 
individuals occupy these healthcare roles which reduced the potential pool of participants for 
these groups. Extensive efforts were made to recruit participants from each of the stakeholder 
groups and colleague referral was predominantly used in Canada to improve the feasibility of 
recruitment.  Second, the study sampled participants from two cities in Canada and India, and the 
findings may not be transferable to other settings or contexts. However, in-depth descriptions of 
the sampling and data collection methods enable readers to determine whether the findings are 
transferable to other contexts. Lastly, social desirability bias may influence participants to 
present their experiences positively. Participant confidentiality and anonymity were emphasized 
prior to beginning the interviews. Further, the HCPs responsible for referring participants were 
not involved in the data collection and analysis, and patients were informed that their quality of 
care would not be influenced by study participation.  
 
Qualitative research provides the opportunity to solicit rich information about the health system 
barriers to and facilitators of CVD medication adherence from patients and the key HCPs 
involved in patient care. Within this study, the selection of stakeholder groups was specific to the 
two contexts. For example, social workers are commonly employed by Canadian hospitals to 
refer financial and social resources to patients and their family members. Conversely, we did not 
include social workers in India because they were not referenced during interviews with the 
patients and HCPs. Further, the country of conduct influenced the type of sampling 
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methodologies used. In accordance with ethical standards in Canada, the recruitment of patients 
through physician’s referral required the physicians to obtain patient consent prior to contact 
from study staff. This requirement was not stipulated by ethical review boards in India. 
Therefore, future qualitative research on health system barriers in other countries should consider 
the context, particularly when selecting key stakeholder groups and implementing sampling 
strategies.  
 
To our knowledge this is the first study to examine the health system related barriers and 
facilitators of medication use in secondary prevention of CVD from the perspectives of key 
HCPs and patients. The strength of this paper is that it highlights the context-specific health 
system factors that influence adherence to cardiovascular medication and demonstrates the 
differences and similarities between the two countries. Another important strength of this study 
is that it provides information on obstacles and facilitators to medication use in India, a low-
income country for which there is limited available literature to inform policy development on 
medication adherence.  
 
Conclusion: 
This study has identified several areas that should be addressed to improve medication adherence 
in secondary prevention of CVD. The barriers that we described herein included high patient 
loads, time constraints, medication availability and affordability, and the absence of written 
counseling. Additionally, monitoring adherence, adherence follow-up by NPHWs, inquiry and 
referral to programs to improve medication affordability, and task shifting were the facilitators 
referred by the stakeholder groups. Our findings provide vital information to HCPs, 
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Barrier and facilitators in Canada and India.  
Barrier Facilitator 
Canada India Canada India 
Mode of counselling Mode of counselling Monitoring adherence Monitoring adherence 
Time constraints Time constraints Family support Family support 
Medication cost Medication cost Addressing poor adherence Inquiring about medication 
affordability 
High patient loads High patient loads Inquiring about medication 
affordability 
 
 Uncomprehensive medication 
counselling 
Adherence follow-up by 
NPHWs 
 
 Resistance to task-shifting Supportive of task-shifting  
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Table 2  
Contrasting key themes between the stakeholders in Canada and India. 
Theme Canada India 
Medication counselling Communicated verbally 
 
Written materials provided to patients by pharmacists 
 
Information communicated: medication purpose, benefits, 
dosage, frequency, side effects, adverse effects, 
contraindications, instructions on how to take 
 




Written materials not provided to patients by HCPs 
 




Joint-decision making practiced by AYUSH physicians  
 
 
Medication adherence Medication adherence assessed by physician/nurse 
practitioners, pharmacists 
 
Methods used to check adherence: biological makers, 
prescription refill history, ask patient about medication use 
 
Methods to address non-adherence: additional counselling and 
education (purpose, benefits, health implications), involve 
family members, recommendation to establish a routine 
 
Patients reported being asked about adherence by their HCPs 
Medication adherence assessed by physicians, nurses 
 
 
Methods used to check adherence: biological markers, ask 
patient about medication use 
 
The doctors mentioned that due to time constraint they were 
unable to ask about adherence during every single visit 
Affordability and drug 
coverage 
Medication coverage discussed with patient: physician/nurse 
practitioner, pharmacist, social worker 
 
HCPs were knowledgeable about resources available to patients 
with affordability issues (government programs, social worker 
consult) 
 
Tailors prescription to patient socioeconomic status: generic 
medication, modified dose and frequency, limit number of 









Tailors prescription to patient socioeconomic status: generic 
medication 
 
Medication costs not advertised or standardized across 
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Medication dispensing fee: $10.50-12.00 per medication  
 
Medication costs not advertised or standardized across 
pharmacies 
 









Medication coverage through government (Universal Health 
Coverage) 




Appointment length: 5-30 minutes 
 
Long wait times to see specialists  
 
Patients dissatisfied with appointment lengths 
 
Constrained by time: physician/nurse practitioners 
Number of patients seen per day: 75-185 
 








Constrained by time: physician, AYUSH practitioners 
Task-shifting Follow-up by NPHWs reinforces counselling 
 
Patients receive counselling from physician/nurse practitioners, 
nurses, pharmacists, social workers 
 
NPHWs renewing and modifying medications was supported by 
physician/nurse practitioners, pharmacists 
 
Access to patient medical history, lab/test results, clinical 
experience needed to manage medications 
 
 
Patients receive counselling from physicians, medical 
residents/students, nurses 
 
NPHWs prescribing, renewing and modifying medications were 
only supported by physicians. Nurses are not capacitated to do 
the same  
 
 
Extensive clinical experience needed to manage medications  
Family support  Involve family members in patient care: physician/nurse 
practitioners, pharmacists 
 
Family involvement: reminding to take medications, picking up 
medications, taking patients to appointments, asking questions 
about care, and motivating patients to take medications  
Involve family members in patient care: physicians, AYUSH 
physicians, pharmacists 
 
Family involvement: reminding to take medications, taking 




Strategies for study rigor 
Criterion Strategies 
Credibility -Included multiple subcases 
-Established trusting investigator-participant relationships 
-Maintained master code book  
-Used several research team members to code the data and have regularly discussions about 
analysis decisions 
-Debriefed  
-Sought substantiation of findings with participants 
Dependability -Adhered to the research protocol  
-Documented choices made about methodologies used 
-Maintained organized paper and electronic databases  
-Composed detailed summary reports for each stakeholder group  
Conformability -Sampled participants from a variety of stakeholder groups 
-Transcribed the interviews verbatim 
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